Completed PHASE4 INTERVENTIONAL NCT00323102

A Study Comparing Two Magnetic Resonance Imaging (MRI) Contrast Agents in MRI of the Brain (ENHANCE)

Phase IV, Double-Blind, Multi-Center, Randomized, Cross-Over Study to Compare 0.10 Mmol/kg of MultiHance With 0.10 Omniscan in Magnetic Resonance Imaging (MRI) of the Brain

Sponsor: Bracco Diagnostics, Inc

Conditions Brain Pathology

Interventions Multihance

Updated 5 times since 2017 Last updated: Jan 18, 2008 Started: May 31, 2006 Completion: Mar 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00323102, this PHASE4 trial focuses on Brain Pathology and remains completed. Sponsored by Bracco Diagnostics, Inc, it has been updated 5 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

May 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bracco Diagnostics, Inc

Data source: Bracco Diagnostics, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Princeton, United States